Guy Young
0000-0001-6013-1254
Publication & Citation Trends
Publications
398 total
Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress
Cited by 0
Semantic Scholar
Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran
Cited by 0
Semantic Scholar
A commitment to global collaboration, welcoming international participation and advancing science for the benefit of patients
Cited by 0
Semantic Scholar
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Cited by 23
Semantic Scholar
Bleeding rates in patients with congenital hemophilia B without inhibitors: A systematic review and meta-analysis
Cited by 0
Semantic Scholar
In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering (simulated fitusiran) using thrombin generation assay
Cited by 0
Semantic Scholar
New fitusiran 10 mg dose increases proportion of people with hemophilia within target antithrombin range of 15–35%
Cited by 0
Semantic Scholar
Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran)
Cited by 0
Semantic Scholar
Research Topics
Hemophilia Treatment and Research
(236)
Blood Coagulation and Thrombosis Mechanisms
(157)
Platelet Disorders and Treatments
(103)
Venous Thromboembolism Diagnosis and Management
(85)
Chronic Myeloid Leukemia Treatments
(40)
Affiliations
Université Claude Bernard Lyon 1
University of Southern California
University of Maryland, Baltimore
Heart Rhythm Society
Cincinnati Children's Hospital Medical Center